… of normal or hyperplasic prostate, primary prostate tumors, lymph-nodes metastases, and
bone metastatic lesions. We observed that all primary prostate cancers expressed CXCR4, …

… prostate cancer models including PC3, DU-145, LNCaP and 22Rv1 cells.31-35 We report
here that in the prostate cancer models … Interesting in these prostate cancer models, lonafanib …

… To evaluate potential antimetastatic effects of AdmIL-12-transduced macrophages in this
prostate cancer model, we counted the number of macroscopic lung metastases on day 21 after …

… from one preclinical study suggested synergism between docetaxel and estramustine (6),
our results, obtained with both in vivo and in vitro models employing three prostate cancer cell …

… cancer cell killing both in vitro and in vivo [14,15,16]. Based on these preclinical successes
with NET models, … to the preclinical studies combining TRT with PARPi in NET models, to the …

… In conclusion, the present study demonstrates that prostate cancer prevention by SFN in a
preclinical mouse model is associated with suppression of fatty acid synthesis and possibly …

… ) is highly expressed in primary prostate cancer and associated skeletal metastases. Here, …
used a preclinical animal model of metastasis in which PC3-ML human prostate cancer cells …

… in preclinical models to better inform future clinical trial design [31]. In this regard, non-invasive
imaging methods can enable determination of the kinetics of tumor response or regrowth …

… Treatment with ZD1839 alone inhibited the growth of LX-1, a lung cancer model with a
low level of EGFR expression, and PC-3, a prostate cancer model with moderate EGFR …

… , and the human cancer is unusually hard to grow in culture or as xenografts even short-term.
The prostate cancer models that do exist are basically rodent models, human cell lines, …